Park Julien H, Hogrebe Max, Grüneberg Marianne, DuChesne Ingrid, von der Heiden Ava L, Reunert Janine, Schlingmann Karl P, Boycott Kym M, Beaulieu Chandree L, Mhanni Aziz A, Innes A Micheil, Hörtnagel Konstanze, Biskup Saskia, Gleixner Eva M, Kurlemann Gerhard, Fiedler Barbara, Omran Heymut, Rutsch Frank, Wada Yoshinao, Tsiakas Konstantinos, Santer René, Nebert Daniel W, Rust Stephan, Marquardt Thorsten
Universitätsklinikum Münster, Klinik und Poliklinik für Kinder- und Jugendmedizin, Albert-Schweitzer-Campus 1, Gebäude A 1, 48149 Münster, Germany.
Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, ON K1H 8L1, Canada.
Am J Hum Genet. 2015 Dec 3;97(6):894-903. doi: 10.1016/j.ajhg.2015.11.003.
SLC39A8 is a membrane transporter responsible for manganese uptake into the cell. Via whole-exome sequencing, we studied a child that presented with cranial asymmetry, severe infantile spasms with hypsarrhythmia, and dysproportionate dwarfism. Analysis of transferrin glycosylation revealed severe dysglycosylation corresponding to a type II congenital disorder of glycosylation (CDG) and the blood manganese levels were below the detection limit. The variants c.112G>C (p.Gly38Arg) and c.1019T>A (p.Ile340Asn) were identified in SLC39A8. A second individual with the variants c.97G>A (p.Val33Met) and c.1004G>C (p.Ser335Thr) on the paternal allele and c.610G>T (p.Gly204Cys) on the maternal allele was identified among a group of unresolved case subjects with CDG. These data demonstrate that variants in SLC39A8 impair the function of manganese-dependent enzymes, most notably β-1,4-galactosyltransferase, a Golgi enzyme essential for biosynthesis of the carbohydrate part of glycoproteins. Impaired galactosylation leads to a severe disorder with deformed skull, severe seizures, short limbs, profound psychomotor retardation, and hearing loss. Oral galactose supplementation is a treatment option and results in complete normalization of glycosylation. SLC39A8 deficiency links a trace element deficiency with inherited glycosylation disorders.
溶质载体家族39成员8(SLC39A8)是一种膜转运蛋白,负责将锰摄入细胞。通过全外显子组测序,我们研究了一名患有颅骨不对称、伴有高峰节律紊乱的严重婴儿痉挛症以及不成比例侏儒症的儿童。转铁蛋白糖基化分析显示严重的糖基化异常,这与II型先天性糖基化障碍(CDG)相对应,且血液中的锰水平低于检测限。在SLC39A8中鉴定出了c.112G>C(p.Gly38Arg)和c.1019T>A(p.Ile340Asn)变异。在一组未确诊的CDG病例受试者中,发现了另一名个体,其父亲等位基因上有c.97G>A(p.Val33Met)和c.1004G>C(p.Ser335Thr)变异,母亲等位基因上有c.610G>T(p.Gly204Cys)变异。这些数据表明,SLC39A8中的变异会损害锰依赖性酶的功能,最显著的是β-1,4-半乳糖基转移酶,这是一种对糖蛋白碳水化合物部分生物合成至关重要的高尔基体酶。半乳糖基化受损会导致一种严重的疾病,表现为颅骨畸形、严重癫痫发作、四肢短小、严重精神运动发育迟缓以及听力丧失。口服半乳糖补充是一种治疗选择,可使糖基化完全恢复正常。SLC39A8缺乏将微量元素缺乏与遗传性糖基化障碍联系了起来。